Preetesh Jain, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into a Phase II trial evaluating the safety and efficacy of acalabrutinib in combination with rituximab as first-line therapy for older patients with mantle cell lymphoma (MCL). Dr Jain highlights the value of exploring chemotherapy-free regimens in this patient population and summarizes the findings of this study. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
